Spirodiketopiperazine-based CCR5 antagonists: Lead optimization from biologically active metabolite
Graphical abstract
Key modification introducing a hydroxyl group on side chain to improve CCR5 antagonistic activity as well as in vitro anti-HIV activity by the application of the metabolite’s information of 1.
References and notes (17)
J. Hepatol.
(2006)et al.Curr. Pharm. Des.
(2006)- et al.
J. Biol. Chem.
(2001)et al.J. Virol.
(2004) - et al.
Curr. Med. Chem.
(2006) - et al.
Nature
(1996)et al.Nature
(1996)et al.Science
(1996)
Cited by (48)
Spirocyclic Scaffolds in Drug Discovery
2017, Comprehensive Medicinal Chemistry IIIUgi/Robinson-Gabriel reactions directed toward the synthesis of 2,4,5-trisubstituted oxazoles
2012, Tetrahedron LettersConcise route to a series of novel 3-(tetrazol-5-yl)quinoxalin-2(1H)-ones
2012, Tetrahedron LettersHIV-1 entry inhibition by small-molecule CCR5 antagonists: A combined molecular modeling and mutant study using a high-throughput assay
2011, VirologyCitation Excerpt :TAK-779 (dimethyl-(tetrahydro-pyran-4-yl)-{4-[(3-p-tolyl-8,9-dihydro-7H-benzocycloheptene-6-carbonyl)-amino]-benzyl}-ammonium chloride; Mr = 531.14) (Shiraishi et al., 2000). Aplaviroc (4-{4-[1-butyl-3-(cyclohexyl-hydroxy-methyl)-2,5-dioxo-1,4,9-triaza-spiro[5.5]undec-9-ylmethyl]-phenoxy}-benzoic acid; Mr = 577.73) (Habashita et al., 2006; Nishizawa et al., 2007, 2010a, 2010b). Vicriviroc ((4,6-dimethyl-pyrimidin-5-yl)-(4-{(S)-4-[(R)-2-methoxy-1-(4-trifluoromethyl-phenyl)-ethyl]-3-methyl-piperazin-1-yl}-4-methyl-piperidin-1-yl)-methanone; Mr = 533.64) (Marozsan et al., 2005).
Spirodiketopiperazine-based CCR5 antagonist: Discovery of an antiretroviral drug candidate
2011, Bioorganic and Medicinal Chemistry Letters